© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Mary Caffrey
Articles
Final Consensus Report on Type 1 Diabetes Released by ADA, EASD
October 04, 2021
Article
Throughout, the guidance from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) calls for respecting the patient’s choices, including the fact that not all patients prefer insulin pumps or can afford them.
SGLT2 Inhibitors, GLP-1 RAs Featured in Prevention Guidelines
October 04, 2021
Article
The prevention document, released during ESC Congress 2021, marked the first update of this section of the guidelines in 8 years. It featured changes that reflect the arrival of a pair of drug classes with proven benefits in CV outcomes but that experts say are underutilized.
Discoveries on Temperature and Touch Win Nobel in Medicine
October 04, 2021
Article
David Julius, PhD, and Ardem Patapoutian, PhD, revealed the cellular mechanics of how sensations of touch translate into heat, cold, or pain. Their work has implications in everything from pain management to regulation of blood pressure to bladder control.
In Oncology Clinical Pathways, the Variability Isn’t With the Drugs
September 25, 2021
Article
Experts who took part in Patient-Centered Oncology Care® 2021 said when guidelines recommend high-cost targeted therapies or immunotherapies, the focus must turn to areas such as imaging, diagnostic tests, and other elements that contribute to the cost of care.
In Cancer Care, Turning Attention to Transitions, SDOH
September 25, 2021
Article
The second day of Patient-Centered Oncology Care® 2021 featured a panel discussion, “Oncology Care Transitions: Bridging the Gaps Across the Patient Journey.”
Understanding Psychographics and How All Health Care Behavior Is Local
September 24, 2021
Article
On the opening day of Patient-Centered Oncology Care, Robert Groves, MD, of Banner | Aetna, discussed the use of psychographics to predict health behavior in local populations.
Frontline Cemiplimab With Chemo Offers Benefits in Advanced NSCLC Regardless of PD-L1 Status
September 19, 2021
Article
Sanofi and Regeneron had previously announced an overall survival advantage of 29% over chemotherapy alone; the combination also had a progression-free survival benefit of 46%.